CD274 and non-small cell lung carcinoma: An analysis by Goldberg et al., including 37 NSCLC patients with previous systemic treatment who relapsed with BM (measuring 5–20 mm) and PD-L1 ≥ 1%, showed a 29.7% CNS overall response rate (ORR) with pembrolizumab [19].